Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins

Considering the accumulating number of preclinical and clinical studies confirming that combined regimens including sorafenib might be beneficial in CLL therapy, in the present study we assess the influence of sorafenib on antitumour activity of anti-CD20 monoclonal antibodies (mAbs) in lymphoma/leukaemia cell lines and primary CLL samples. We observe that sorafenib potentiates antitumour effects of anti-CD20 mAbs, an effect likely mediated by downregulation of membrane-bound complement regulatory proteins (mCRPs).
As anti-CD20 mAbs also activate antibody-dependent cellmediated cytotoxicity (ADCC), we sought to determine the influence of sorafenib on natural killer (NK) cells. The results of preclinical studies reporting immunoregulatory effects of sorafenib on NK cells activity are controversial and not conclusive. For example, sorafenib was shown to alter the microenvironment of hepatocellular carcinomas and trigger activation of NK cells by restoring classical macrophage polarization. 6 Moreover, sorafenib sensitized hepatocellular carcinoma cells to NK cell-mediated functions by Figure 1. Sorafenib potentiates R-CDC and decreases surface levels of mCRPs in various lymphoma/leukaemia cell lines. (a) In the CDC assay, 100 000 cells (control or pretreated with sorafenib for 48 h) were incubated with rituximab (1-100 μg/ml) and 10% human plasma as a source of complement for 60 min at 37°C in fetal bovine serum (FBS)-free RPMI medium. After incubation, MTT reduction assay was performed as described elsewhere. 16 GraphPad Software (La Jolla, CA, USA) was used to determine statistical significance with Mann-Whitnney U test, *Po0.05 vs control. (b) 500 000 cells (control or pretreated with sorafenib for 48 h) were incubated for 30 min in FBS-free medium at 37°C with increasing concentrations of rituximab and 10% human plasma. After incubation, cells were washed with ice-cold phosphate-buffered saline (PBS), centrifuged and stained with anti-MAC primary antibody (mouse monoclonal, clone aE11, Dako (Glostrup, Denmark), final concentration 250 ng/test). After 30-min incubation on ice, cells were washed and incubated for 30 min at room temperature (RT) in the dark with secondary antibody (donkey, anti-mouse-IgG-Alexa488-conjugated, 1:100, Life Technologies, Waltham, MA, USA). Cells were analysed on a FACScan (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) using the CellQuest Pro Software Version 5.2 (BD Biosciences, San Jose, CA, USA). Statistical significance was determined with two-way analysis of variance (ANOVA) test with Bonferroni's correction, ***Po0.001 vs control. (c) CDC assay with rituximab or ofatumumab using MEC-1 cells was performed as described above. Statistical significance was determined with Mann-Whitnney U test, *Po0.05 vs control. (d) For the degranulation assay, natural killer (NK) cells were negatively isolated from peripheral blood mononuclear cells of healthy donors using the EasySep Human NK cell Enrichment Kit (STEMCELL Technologies, Vancouver, BC, Canada) and stimulated overnight with human recombinant interleukin-2 (Proleukin, 100 IU/ml; Chiron, Barcelona, Spain) and interferon-α (Roferon-A, 100 IU/ml; F. Hoffmann-La Roche AG, Basel, Switzerland). NK effector cells were incubated with target Raji cells (at E:T ratio 1:1) and rituximab (100 μg/ml) in the presence of anti-CD107a fluorescein isothiocyanate (FITC)-conjugated antibody (BD Biosciences), GolgiStop (BD Biosciences) and sorafenib for 4 h (left and right panels). Additionally, in preincubation/co-incubation assay (right panel) both Raji and NK effector cells were inhibiting the shedding of major histocompatibility class I-related chain A ectodomain. 7 When combined with human anti-glypican 3 antibody, sorafenib showed additive effect on ADCC in a xenograft model of human liver cancer in vivo. 8 However, sorafenib has also been reported to have a suppressive effect on NK cells acting directly on NK cell proliferation and function by inhibition of phosphoinositide 3-kinase and extracellular signalregulated kinase signalling pathways. 9,10 In line with these latter reports, we observe a suppression of NK cell function in ADCC assay measuring CD107a mobilization (Figure 1d, left panel) in a model where both NK cells and target cells are incubated for 4 h with rituximab in the presence of sorafenib. However, we also employed a clinically more relevant model, where both target Raji cells and effector NK cells are preincubated with sorafenib for 48 h and further co-incubated for 4 h with rituximab in the presence of sorafenib. In this model, sorafenib has no influence on rituximabmediated ADCC (Figure 1d, right panel) indicating the possibility that sorafenib inhibits the activity of NK cells, and it simultaneously sensitizes target tumour cells to NK cell-mediated killing. Further studies are clearly needed to determine in more detail the impact of sorafenib on the complex interplay between target cancer cells and effector NK cells.
Letter to the Editor To further determine the mechanisms of potentiated CDC, we measured the expression levels of CD20 as well as other B-cell membrane proteins known to regulate CDC. Flow cytometry reveals a significant increase of surface CD20 levels in Raji ( Figure 1e) and MEC-1 cells (Figure 1f), as well as an increased binding of rituximab to Raji cells (data not shown). Simultaneously, we observe that sorafenib in a dose-dependent manner significantly decreases surface levels of mCRPs, including CD46 (Figures 1e and f), CD55 (Figure 1e) and CD59 (Figure 1f). Also, in a set of 22 primary tumour samples preincubated with sorafenib for 48 h we observe significantly decreased surface levels of CD46, CD55 and CD59 (Figure 2a, Supplementary Figure S2A). At the same time, the levels of surface CD20, as well as of other antigens such as CD19, CD37 and CD38, remain roughly unchanged in primary CLL cells incubated with sorafenib (Supplementary Figure S2B).
In nine consecutive primary CLL samples, sorafenib significantly potentiates O-CDC (at doses 1 and 10 μg/ml) (Figure 2b). Collectively, we demonstrate that sorafenib significantly downregulates mCRPs and this effect is sufficient to sensitize tumour cells to anti-CD20 mAbs-mediated CDC.
Sorafenib has been reported to inhibit phosphorylation of signal transducer and activator of transcription 3 (STAT3) and to block STAT3 signalling in several tumour cell lines. Some in vitro studies suggest that constitutive phosphorylation of STAT3 is a hallmark of CLL and can be considered as a therapeutic target in this disease. 11 Sorafenib targets Raf-1 and receptor tyrosine kinases, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor and c-Kit, and inhibits STAT3 activity as a point of convergence for these tyrosine kinases. Consistently with these findings, we observe a dose-dependent inhibition of STAT3  Figure S3A). Noteworthy, CD46 promoter contains the STAT3 consensus-binding site, 12 and both CD46 and CD55 promoters were found to bind STAT3 transcription factor. 13 We also analysed the promoters of CD55 and CD59 and found several putative STAT3-binding sites (Supplementary Figure S4). Somewhat surprisingly, a transcriptional analysis of cells reveals that mRNA levels of mCRPs in Raji cells (Supplementary Figure S3B) and primary CLL cells (Supplementary Figure S3C) do not change upon incubation with sorafenib as measured with quantitative reverse transcriptase-PCR. It is possible that STAT3-mediated effects induced by sorafenib are carried out by other nontranscriptional mechanisms. It has been already shown that independently of transcriptional activity STAT3 can serve as a protein scaffold to facilitate the interaction between phosphatidylinositol 3-kinase and the type I interferon receptor. 14 To further determine whether downregulation of mCRPs is attributed to pSTAT3 inhibition, we assessed the effects of SC-1, a novel sorafenib analogue devoid of Raf-1 but retaining potent STAT3 inhibitory activity, on mCRPs levels. SC-1 dose-dependently downregulates CD46, CD55 and CD59 levels in MEC-1 cells (Figure 2c). Importantly, mCRPs downregulation corresponds with sensitization of MEC-1 cells to both R-CDC and O-CDC ( Figure 2d). Collectively, our results indicate that STAT3 may potentially have a role in the regulation of mCRPs' levels. However, further studies are required to fully elucidate the mechanisms of this phenomenon.
Activation of classical complement cascade has a role in the therapeutic efficacy of several unconjugated therapeutic antibodies. For example, in unmanipulated whole blood assays the activity of ofatumumab has been shown to be fully complement-dependent and further increased by blocking CD55 and CD59. 15 Induction of CDC is also important for alemtuzumab action. Moreover, while trastuzumab alone does not induce CDC, in combination with pertuzumab it kills tumour cells in a complement-dependent manner. Although tumour cells can overexpress mCRPs, neutralization or downregulation of complement inhibitors has been proposed to increase mAb-induced CDC. Here we add another potential therapeutic approach-a drug-mediated downregulation of mCRPs levels that seems to be of clinical significance.
In many in vitro studies sorafenib as a single-agent displays a strong pro-apoptotic activity in CLL cells, even in the presence of prosurvival factors derived from stromal cells. Our in vitro studies, where sorafenib shows potentiated antitumour effects when combined with anti-CD20 mAbs, indicate that sorafenib constitutes a promising strategy for sensitization of tumour cells to mAb-mediated CDC and support its use as a new therapeutic option in CLL.